The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

Novo Nordisk NVO announced that the European Commission (EC) has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity. This provides physicians ...

Novo Nordisk A/S NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) adopted a positive opinion, recommending a label update of its blockbuster ...

The European Commission has granted final approval of a higher 7.2 mg maintenance dose of Wegovy® (semaglutide) for adults ...

Bagsværd, Denmark, 25 July 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an ...

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company's two obesity drug ...

Novo Nordisk A/S (NYSE:NVO) is one of the Best Non-US Stocks to Buy According to Hedge Funds. On December 12, Novo Nordisk A/S (NYSE:NVO) announced receiving a positive opinion by the European ...

ATLANTA — Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity, diabetes, and a common type of heart failure, boosting Novo’s attempt to get the popular drug ...

By Amina Niasse NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health will start offering compounded ...

Novo’s 90-second ad features a coterie of celebs promoting the oral version of its blockbuster weight loss drug Wegovy.